Bluye Water Acquisition in an 8-K filing included a slide deck highlighting its proposed merger with Clarus Therapeutics.
The agreement values Clarus at $379 million on a fully diluted basis, assuming no redemptions by Blue Water stockholders. Current Clarus stakeholders will invest an additional $25 million in the therapeutics company.
Pending shareholder approval, the deal is expected to close in the third quarter. Read more.
